<p>The British maker of Nurofen painkillers and Strepsils and Lemsip cold remedies will pay 1,171 pence per SSL International share, representing a 33 per cent premium to Tuesday’s closing price. <br /><br />The price includes the 8 pence final dividend. Reckitt Chief Executive Bart Becht said the deal should increase the group’s health and personal care net revenues by over 36 per cent to around £2.8 billion, one third of the group’s total revenues.<br /><br />“The acquisition will increase our health & personal care net revenue by over 36 per cent to approximately £2.8 billion, one third of group’s total net revenue,” Becht noted. <br /><br />SSL’s board recommended offer, which Chairman Gerald Corbett said was four times the level of the company’s share price five years ago.<br /></p>
<p>The British maker of Nurofen painkillers and Strepsils and Lemsip cold remedies will pay 1,171 pence per SSL International share, representing a 33 per cent premium to Tuesday’s closing price. <br /><br />The price includes the 8 pence final dividend. Reckitt Chief Executive Bart Becht said the deal should increase the group’s health and personal care net revenues by over 36 per cent to around £2.8 billion, one third of the group’s total revenues.<br /><br />“The acquisition will increase our health & personal care net revenue by over 36 per cent to approximately £2.8 billion, one third of group’s total net revenue,” Becht noted. <br /><br />SSL’s board recommended offer, which Chairman Gerald Corbett said was four times the level of the company’s share price five years ago.<br /></p>